[Federal Register Volume 78, Number 104 (Thursday, May 30, 2013)]
[Notices]
[Page 32367]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-12854]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[S-32-2013]


Approval of Subzone Status; Teva Pharmaceuticals USA, Inc.; North 
Wales, Chalfont, Kutztown and Sellersville, Pennsylvania

    On March 18, 2013, the Executive Secretary of the Foreign-Trade 
Zones (FTZ) Board docketed an application submitted by the Philadelphia 
Regional Port Authority, grantee of FTZ 35, requesting subzone status 
subject to the existing activation limit of FTZ 35, on behalf of Teva 
Pharmaceuticals USA, Inc., in North Wales, Chalfont, Kutztown and 
Sellersville, Pennsylvania.
    The application was processed in accordance with the FTZ Act and 
Regulations, including notice in the Federal Register inviting public 
comment (78 FR 17634-17635, 3-22-2013). The FTZ staff examiner reviewed 
the application and determined that it meets the criteria for approval. 
Pursuant to the authority delegated to the FTZ Board Executive 
Secretary (15 CFR 400.36(f)), the application to establish Subzone 38F 
is approved, subject to the FTZ Act and the Board's regulations, 
including Section 400.13 and further subject to FTZ 35's 2,000-acre 
activation limit.

    Dated: May 23, 2013.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2013-12854 Filed 5-29-13; 8:45 am]
BILLING CODE 3510-DS-P